米彦军 apatinib (yn968d1) 儿reverses multidrug …：米彦军阿帕替尼（yn968d1）逆转多药耐药….pptVIP

Background Background Tyrosine kinase inhibitors (TKIs) belong to a new class of anticancer drugs. TKIs including lapatinib, erlotinib and sunitinib, have been shown to overcome ABC transporters-mediated MDR in cancer cells. Apatinib (YN968D1) is an oral small-molecule TKI that targets VEGFR-2, RET, c-Kit and c-Src tyrosine kinases. It is conceivable that apatinib may inhibit functions of ABC transporters by binding to their ATP-binding sites. Cytotoxicity of apatinib alone in all experimental cell lines Potentiation of antitumor effects of paclitaxel by apatinib in a xenograft model of KBv